Hims & Hers Health plans to launch generic of Novo Nordisk's Victoza

Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025, per a Reuters report.

"We have already confirmed a core supplier for this addition and over the next few months expect to finish completing test and batch validation, as well as confirming certificates of analysis," the company said, per the report.

Liraglutide, used to treat Type 2 diabetes under the brand name Victoza, belongs to the first generation of drugs known as GLP-1 agonists, which curb appetite and help control blood sugar.

[Read more: Hims & Hers Health offers GLP-1 injections]

Hims & Hers currently offers compounded GLP-1 weight-loss injections at $199 per month and weight management oral medication kits at $79 per month.